Established in one of the largest prevention studies in HAE1-5
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.1
No incidence of anaphylaxis in the pivotal trial.1
Injection site reactions were the most common adverse reactions (ARs).1
SebastianReal TAKHZYRO patient
every 2 weeks
every 4 weeks
*≥10% in any TAKHZYRO group that also occurred at a higher rate than placebo group.
†Additional injection site reactions included hematoma, hemorrhage, pruritus, swelling, induration, paresthesia, reaction, warmth, edema, and rash.
‡Includes upper respiratory infection, viral upper respiratory infection.
§Includes headache, tension headache, sinus headache.
IIIncludes rash, rash maculopapular, rash erythematous.
Consistent safety profile seen in 212 patients in a long-term study1
Safety data from an interim analysis of patients taking TAKHZYRO for an average of 20 months5
Hypersensitivity reactions (2%, n=4)¶ were reported in the study.5
6 patients discontinued due to treatment-emergent adverse events.5
No treatment-related serious adverse events or anaphylaxis were observed.5
¶Related, treatment-emergent hypersensitivity reactions